Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics

BACKGROUND: Available literature supports the use of long-acting injectable (LAI) antipsychotics over short-acting oral (SAO) formulations. The majority of evidence is centered on patients with schizophrenia insured under the Medicaid benefit. OBJECTIVE: To assess real-world clinical and economic ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kheloussi, Steven, Oberlin, John, Trauger, Madison, Testa, Nicholas D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372965/
https://www.ncbi.nlm.nih.gov/pubmed/36125056
http://dx.doi.org/10.18553/jmcp.2022.28.10.1130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372965/
https://www.ncbi.nlm.nih.gov/pubmed/36125056
http://dx.doi.org/10.18553/jmcp.2022.28.10.1130

Ejemplares similares